The California Institute of Regenerative Medicine has a new strategic plan, reports the Nature News Blog. For the next five years, CIRM will shift its focus away from basic research toward clinical applications. "The first stage of CIRM was really exploring the field," says Ellen Feigal, the institute's senior vice president of R&D.